Cargando…
Prostaglandin E2 Receptor 4 (EP4) as a Therapeutic Target to Impede Breast Cancer-Associated Angiogenesis and Lymphangiogenesis
SIMPLE SUMMARY: The formation of new blood (angiogenesis) and lymphatic (lymphangiogenesis) vessels are major events associated with most epithelial malignancies, including breast cancer. Inflammation is a key mediator of both processes, hijacked by many cancers by the aberrant expression of the inf...
Autores principales: | De Paz Linares, Guillermo Antonio, Opperman, Reid Morgan, Majumder, Mousumi, Lala, Peeyush K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956318/ https://www.ncbi.nlm.nih.gov/pubmed/33668160 http://dx.doi.org/10.3390/cancers13050942 |
Ejemplares similares
-
Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions
por: Majumder, Mousumi, et al.
Publicado: (2014) -
PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells
por: Nandi, Pinki, et al.
Publicado: (2017) -
EP4 as a Therapeutic Target for Aggressive Human Breast Cancer
por: Majumder, Mousumi, et al.
Publicado: (2018) -
The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis
por: Tutunea-Fatan, Elena, et al.
Publicado: (2015) -
Signaling of Prostaglandin E Receptors, EP3 and EP4 Facilitates Wound Healing and Lymphangiogenesis with Enhanced Recruitment of M2 Macrophages in Mice
por: Hosono, Kanako, et al.
Publicado: (2016)